<DOC>
	<DOCNO>NCT02071043</DOCNO>
	<brief_summary>Gastric cancer para-aortic lymph node ( PAN ) involvement regard advanced disease , chemotherapy recommend guideline . In unresectable case , neoadjuvant chemotherapy could prolong survival conversion resectability could achieve .</brief_summary>
	<brief_title>Trial Xeloda Oxaliplatin ( XELOX ) Neo-adjuvant Chemotherapy Followed Surgery Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Gastric gastroesophageal adenocarcinoma proven histologically . 2 . Has paraaortic lymph node metastasis ( PAN define nodes region upper margin celiac artery upper border inferior mesenteric artery ( station . 16a2/16b1 ) ) 3 . Eastern Cooperative Oncology Group performance status 0 1 . 4 . Life expectancy ≥12 week . 5 . Adequate hematological function : Neutrophil count ≥ 1.5 × 109/L , Platelets ≥ 100 × 109/L Hemoglobin ≥9 g/dL ( may transfuse maintain exceed level ) . Adequate liver function : Total bilirubin ≤ 1.5 × upper limit normal ( ULN ) ; AST ( SGOT ) ALT ( SGPT ) &lt; 2.5 × ULN , ALP ≤ 2.5 × upper limit normal ( ULN ) ; ALB ≥30g/L。 Adequate renal function : Serum creatinine ≤ 1.25 x ULN , creatinine clearance ≥ 60 ml/min . 6 . Female subject pregnant breastfeeding . 7 . No serious concomitant disease threaten survival patient le 5 year . 1 . Serious concomitant disorder would compromise safety patient compromise patient 's ability complete study , discretion investigator . 2 . History another malignancy last 5 year exception follow : Any previous palliative , adjuvant neoadjuvant chemotherapy and/or radiotherapy . Prior treatment locally advance metastatic gastric cancer . 3 . Any metastatic disease render patient ineligible accord AJCC stag manual ( liver，lung，etc） . 4 . Active infection opinion investigator would compromise patient 's ability tolerate therapy . 5 . Poorly control diabetes mellitus fast blood sugar &gt; 18 mm . Second primary malignancy clinically detectable time consideration study enrollment . 6 . Unstable , persistent cardiac disease despite medicinal treatment , myocardial infarction within 6 month start trial 7 . Previous surgery primary tumour ; Prior palliative surgery ( open closure , passage operation ) 8 . Any type tumour ( e.g . leiomyosarcoma , lymphoma ) secondary malignancy , except basal cell skin carcinoma basal cell carcinoma situ cervix already successfully treat</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>neo-adjuvant chemotherapy</keyword>
	<keyword>advanced gastric cancer patient</keyword>
	<keyword>para-aortic lymph node metastasis</keyword>
</DOC>